We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pro-Gastrin-Releasing Peptide (ProGRP) - ein neuer Tumormarker beim kleinzelligen Bronchialkarzinom.
- Authors
Stieber, Petra; Dienemann, H.; Schmitt, Ursula Maria; Reinmiedl, Judith; Hasholzner, Ute; Reiter, W.; Hofmann, Karin; Schalhorn, A.; K. Yamaguchi
- Abstract
Gastrin-releasing peptide (GRP), a gut hormone and the mammalian counterpart of amphibian bombesin, has been reported during recent years to be produced by cells of small-cell lung carcinoma. Using recombinant ProGRP Yamaguchi et al. developed an enzyme immunoassay for the measurement of the more stable precursor of GRP. Using the sera of 604 patients with various benign diseases and malignant disorders of the lung we focused our interest on the clinical relevance of ProGRP in small cell and non-small- cell lung cancer in comparison to well established tumour-associated antigens such as neuron-specific enolase (NSE), CYFRA 21-1 and the carcinoembryonic antigen (CEA). Fixing specificity at 95% for benign lung diseases ProGRP and NSE showed comparable sensitivities (47% versus 45%) in small-cell lung cancer. ProGRP showed a few more positive test results than NSE, but in several cases ProGRP reached much higher values than NSE. From our data in small-cell lung carcinomas, ProGRP alone was expressed in as many patients as 'NSE alone, corresponding to a combined sensitivity of 62%. With 63% sensitivity CYFRA 21-1 proved again to be the leading marker in non-small-cell lung carcinoma whereas ProGRP and also NSE seldom showed a positive test result. Therefore, because of high levels ProGRP and also NSE enable diagnosis of small-cell lung carcinoma in patients with lung tumours of unknown origin.
- Publication
Journal of Laboratory Medicine / Laboratoriums Medizin, 1997, Vol 21, Issue 6, p336
- ISSN
0342-3026
- Publication type
Article